Sisk is close to finalizing an agreement to take over the completion of ISG’s £200m vaccine manufacturing facility on Teesside, following ISG’s collapse. The project, known as Project Borealis, was initially led by ISG before it entered administration nearly two weeks ago.
Sisk’s life sciences division is in advanced negotiations with the client, Fujifilm Diosynth Biotechnologies, to resume work on the site. This news offers relief to subcontractors affected by ISG’s downfall, as many are eager for a quick restart to avoid further delays and financial fallout.
Project Borealis, a multi-phase bio-tech manufacturing facility located at Fujifilm Diosynth Biotechnologies’ Billingham site, was halted abruptly when ISG’s administration was announced. Subcontractors, including Irish M&E firm Jones Engineering, stopped work on Phase 1, the most advanced section, on Thursday, September 19th.
Talks between Sisk and Fujifilm have been ongoing, and if an agreement is reached, work could resume as early as next week. The restart of this significant project brings hope to other subcontractors nationwide, who are watching closely to see if their projects might similarly resume under new contractors.